Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has issued an update.
Neurizon Therapeutics Limited has reported the expiry of 3 million unlisted options exercisable at $0.15 that were due to lapse on 31 December 2025, with none of these options being exercised before their expiry. The cessation of these securities reduces the pool of potential future share dilution for existing investors and marginally simplifies the company’s capital structure, though it does not immediately alter the number of shares on issue or directly affect day-to-day operations.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited, listed on the ASX under the code NUZ, operates in the biotechnology/pharmaceutical sector, focusing on therapeutic drug development. The company’s activities center on researching and commercializing treatments, positioning it within the broader life sciences and medical innovation market.
Average Trading Volume: 728,948
Technical Sentiment Signal: Sell
Current Market Cap: A$61.51M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.